Uncategorized
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline water and flavor-infused water products, today announced that it is partnering with Hensley Beverage Company, a local direct-store-delivery (“DSD”) provider, to distribute its beverage brands across Arizona. “We are pleased to announce we have entered into an agreement with Hensley Beverage Company, an Anheuser-Busch InBev distributor,” said Ricky Wright, president and CEO of The Alkaline Water Company. “Hensley is one of the largest and most respected family-owned beverage distributors in the nation. They service all of Arizona, and its customer base includes over 9,000 retail locations. Under this agreement, Hensley will carry the full line of our smooth tasting Alkaline88 water portfolio and our A88 Infused flavored waters.”
To view the full press release, visit: https://cnw.fm/1HTBk
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s flavor-infused water. To learn more about the company, visit www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
NetworkNewsWire Editorial Coverage: An estimated 17% of the world, or 1.3 billion people, use tobacco, creating a global tobacco market that approached one trillion dollars in 2020. Given all of the health risks associated with smoking, a significant portion of those tobacco users are looking for other smoking options, alternative that offer a smooth and satisfying tobacco-free and nicotine-free experience that tastes as well as or better than traditional tobacco products. For many, eliminating nicotine is a priority. Addressing this problem head on and carving out a new market niche, TAAT(TM) Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) (Profile) recently launched TAAT, a nicotine-free and tobacco-free cigarette, available in three flavors: Original, Smooth and Menthol. The retail launch included a comprehensive unveil in Ohio, and an e-commerce site went live last week. The company is reshaping the smoking experience by offering a smokable alternative. TAAT is looking to grab significant shelf space alongside the big tobacco oligopoly of Philip Morris International Inc. (NYSE: PM), Altria Group Inc. (NYSE: MO) and British American Tobacco Industries p.l.c. ADR (NYSE: BTI) as well as Chinese vaping giant RLX Technology Inc (NYSE: RLX).
- TAAT looking to capture a sizeable share of the $100-plus billion U.S. tobacco market.
- The Beyond Tobacco(TM) base material undergoes patented 14-step refining process to taste, smell and smoke like tobacco.
- TAAT CEO Setti Coscarella, CRO Tim Corkum bring decades of tobacco industry experience after serving in leadership roles at Marlboro maker Philip Morris.
- TAAT has recently been named to CSE25(TM) as one of the biggest CSE Composite Index companies by market capitalization.
Bringing a Substitution Model to Smoking
Health and wellness has become a top priority in today’s world, creating a global climate of consumers clamoring for choices that offer the same experiences they’ve come to enjoy but with different ingredients. This is on full display with the surging popularity of alternative food and beverages that create the same feeling that one is accustomed with only a change in ingredients. Today, burgers and seafood look, smell and taste like hamburger and crabmeat, respectively, while being made from plants. Zero percent alcohol wine and beer that cut out traditional ingredients such as gluten are so refined that they can fool even the most discerning palates of alcohol connoisseurs.
That same sentiment is carrying over to the world of tobacco, where enthusiastic adult smokers are eagerly looking for different options. Many want tobacco-free and nicotine-free alternatives; however, they also seem to prefer the sensation and experience of a combustible product.
Same Format, Different Ingredients Model
TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) has brought the “same format, different ingredients” model to the smoking market like no one before. With senior leadership coming directly from big tobacco, the life sciences company has developed its products to closely replicate a conventional tobacco cigarette while changing the composition so it doesn’t include tobacco.
Based on consumer response, TAAT hits its target dead center. Early market testing revealed no significant experiential differences between TAAT and tobacco cigarettes. That response speaks volumes as TAAT looks to capture a sizeable share of the $100-plus billion U.S. tobacco market.
Furthermore, the company is using an attractive pricing structure to offer a substantial consumer savings compared to top-selling tobacco cigarettes. As TAAT embarks on a nationwide launch after commencing sales in Ohio late in December 2020, management has engaged a leading consumer packaged goods sales agency to accelerate brick-and-mortar retail sales while online sales are generated through a brand-new online portal.
Meticulously Crafted, Perfectly Priced
The Beyond Tobacco(TM) base material of TAAT undergoes a 14-step process to taste, smell and smoke just like tobacco, which includes a patent-pending refinement process. In doing so, TAAT touches the all-important five sensory elements of a smoking tobacco cigarette. This includes nearly identical packaging and smoke volume (visual), crackling sound upon lighting (auditory), a tobacco-like scent while burning (smell), and “hand-to-mouth” motor habits (touch). Ashes can even be “flicked” in a similar manner to tobacco ashes. TAAT completes the sensory experience by using its patent-pending Beyond Tobacco base material to create a tobacco-like taste without using nicotine or tobacco.
The formulation provides a competitive edge over other types of tobacco alternatives currently available. Primarily, it appeals to current smokers aged 21 years and older who are looking to keep the experiences they enjoy while leaving the nicotine behind. Even better, smokers aged 21+ who switch to TAAT are not replacing one nicotine product with another, as is often the case with alternatives such as vaping.
In addition, while the packaging and smoking experience may be nearly the same as a tobacco cigarette, the price point for TAAT’s product offering is far different. A pack of TAAT is priced at $3.99 in Ohio, approximately a 43% savings from a pack of Marlboro, which costs about $7.00 per pack.
Marketing Blitz and Expansion
While meticulous and methodical in its development, TAAT is starting to hit the gas in expansion. Subsequent to its December launch in Ohio, TAAT initiated a 60-day, digital, out-of-home (DooH) advertising campaign composed of video ads streaming on thousands of video screens on gasoline pumps across a network of chain and independent gas stations in Ohio; the videos promoting TAAT products target smokers aged 21 and older. The “out-of-home” video ads are running concurrently with other promotional initiatives targeting legal-aged smokers, including a digital marketing campaign for the TryTAAT landing page.
In just two months of being sold at retail, the brand is gaining traction as evidenced by 60% of retailers that have carried TAAT for three or more weeks placing at least one reorder, with many reorders increasing in volume. The Menthol variety was the first to be sold out and reordered during its first weeks of availability in Ohio. The TryTAAT campaign is also being warmly received, considering that one-third of all visitors to the page had submitted requests for a sample pack of TAAT, representing an exceptionally high conversion rate by industry standards.
This month, TAAT engaged CROSSMARK Inc., a Texas-based omnichannel sales agency with more than 25,000 employees serving all of North America. TAAT will leverage CROSSMARK’s existing relationships with more than 100,000 convenience retailers directly serviced by the firm to potentially expand availability of TAAT products in Ohio and elsewhere in the United States. The new relationship dovetails perfectly with TAAT’s launch of its new ecommerce website this month, which sold more than CAD $50,000 of product in its first 48 hours.
Tobacco Industry Acumen
TAAT has assembled a world-class management team with diverse experience deeply rooted in the tobacco industry. CEO Setti Coscarella not only spent years working in private equity and banking, he was also a lead strategist for Reduced-Risk Products (“RRP”) in Canada for international cigarette behemoth Philip Morris International where he developed deep expertise in commercializing smoking alternatives.
TAAT chief revenue officer Tim Corkum also has a long history in tobacco, working various senior roles involving sales, supply chain management and commercialization during his 21 years at Philip Morris across Canada and in the Caribbean.
Under this leadership, TAAT has raised capital and organized for expansion by doubling production capacity and filing trademarks in 54 countries. In October, TAAT received $5 million in a private placement from a group of investors led by Debbie Chang, co-founder of Horizons Ventures (in her personal capacity), a Hong Kong-based venture capital firm. As management evaluates domestic and international commercialization, the company optimized its Las Vegas, Nevada, processing facility with automated workflows and adding new machinery to efficiently increase production Beyond Tobacco base material by 100%.
These efforts and leadership have not gone unrecognized. TAAT share price has appreciated substantially, including a big jump in September that led to TAAT being added to two Canadian stock indices in December 2020 including the CSE Composite Index as well as its CSE25(TM) index, an exclusive subset featuring the 25 largest companies in the index by market capitalization.
Market Opportunity
With hundreds of millions of people around the world smoking cigarettes and many aspiring to leave nicotine behind, a huge opportunity exists for savvy companies ready to seize the moment. Even with the negative effects of vaping being fleshed out as the market matures, Grand View Research still sees 23.8% growth in the space from 2020 to 2027, ultimately reaching a projected $67.3 billion.
Philip Morris International Inc. (NYSE: PM), maker of Marlboro, Virginia Slims and some of the world’s most popular cigarette brands, made the decision in 2016 to transform its business, moving away from combustible products to smoke-free ways to deliver nicotine. The company set a goal of getting 40 million of its customers to quit smoking by 2025, of which it touted making substantial progress in a 2019 report showing a reduction in cigarette shipments and a rise in shipments of its smoke-free products.
PM parent company Altria Group Inc. (NYSE: MO) has a 10-year vision to lead the transition of adult smokers to a noncombustible future. The company is the owner of highly popular smokeless tobacco brands such as Copenhagen and Skoal, in addition to a large stake in Juul Labs, a top-selling e-cigarette brand in the United States. Altria is also a large shareholder in Cronos, which it believes it can help position in the legal cannabis market as part of encouraging consumers to move beyond smoking to potentially reduced harm alternatives.
British American Tobacco Industries p.l.c. ADR (NYSE: BTI), which makes Camel and Newport cigarettes and Grizzly smokeless tobacco, has also focused some R&D and marketing on less-risky products to give its customers more options, including its Vuse (vapor), glo (tobacco heating) and Velo (nicotine pouch) products. In the company’s 2018 Harm Reduction Focus Report, BAT lays out its commitment to support consumer use of what are labeled PRRPs, o potentially reduced-risk products.
RLX Technology Inc. (NYSE: RLX) made a big splash with its initial public offering in January, bumping up its IPO price from $8 per share to $12 per share before opening at $22.34 as investors jumped headlong into the Chinese vaping company. Ultimately, the company jumped 86% in its U.S. stock market debut, giving the Chinese vaping firm a market capitalization of nearly $35 billion. While RLX Technology sells products in 13 countries, its bread and butter is China, where it controls 62% of the market with only a 1.2% penetration rate.
With smokers aged 21 and above looking for alternatives that provide the pleasure of smoking without the nicotine or tobacco, the tobacco industry is clearly showing an interest in widening its reach and providing choices to its consumers.
For more information about TAAT Lifestyle & Wellness Ltd., please visit www.TAATGlobal.com.
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
SRAX (NASDAQ: SRAX) is focused on unlocking data and insights through its software-as-a-service (“Saas”) platform, Sequire. The platform helps its users unlock the power of data so they can activate marketing campaigns that engage both current and prospective investors. A recent article discussing this reads, “Sequire is the answer for many public companies looking to harness the power of big data for reliable analytics derived from the platform’s 3 million+ active users, a group which includes investors and traders from over 90 public companies (https://ibn.fm/tuibH). The platform’s unique tools help users obtain insights through investor intelligence and outreach, warrant tracking, survey creation, event promotion and roadshows.”
To view the full article, visit https://ibn.fm/cVVY8
About SRAX Inc.
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider, today announced that it has entered into a partnership with HubSpot Inc. (NYSE: HUBS), a leading growth platform, to empower HubSpot’s global customers in the areas of WeChat commerce, CRM and marketing SaaS solutions in China. According to the update, the partnership is enabled through iClick’s acquisition of the business of Parllay, a long-term technology partner of HubSpot. “HubSpot and iClick’s integrated client service capabilities are a game changer for giving companies a truly leading SaaS offering to support their sales and marketing needs in China,” said Jian “T.J.” Tang, chief executive officer and co-founder of iClick. “Leveraging the foundation between HubSpot and Parllay, we have high conviction that this partnership that will lay the groundwork for helping more top international brands achieve success in the China market.”
To view the full press release, visit http://ibn.fm/w8nir
About iClick Interactive Asia Group Limited
iClick Interactive Asia Group is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, iClick’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide, including Asia and Europe. For more information about the company, please visit ir.i-Click.com.
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
For more information, please visit https://www.ChineseWire.com
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: https://www.ChineseWire.com/Disclaimer
ChineseWire
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com
ChineseWire is part of the InvestorBrandNetwork.
The ocean waters that surround Papua New Guinea and Eastern Indonesia lie in a biodiverse Coral Triangle, which is home to some of the world’s most highly endangered and concentrated coral reefs. Apart from being internationally significant ecological sites, these reefs are also habitats for a few vital subsistence and commercial fisheries, which are crucial to the lives of the local communities.
At the same time, the area, which is rich in nickel deposits, is attracting the attention of manufacturers of electric vehicles worldwide. Reason being, electric vehicles rely on batteries that contain minerals such as cobalt, lithium and nickel.
The global demand for nickel is expected to grow nearly six times by the year 2030. This would explain why Indonesia, which is currently the biggest producer of nickel globally, is trying to significantly increase nickel production in order to meet the demand.
To do so, however, mining firms would have to find a different way to mine that would not include the disposal of mine waste, known as tailings, in the sea. For years, this pollution problem has affected Indonesia’s mining industry. Indonesians have been against this practice, quoting evidence that the tailings would strain fisheries and eliminate fragile reefs, which are already being affected by the coal plants that are currently used to power existing operations.
Last year, Tesla CEL Elon Musk vowed to award a huge contract to any company that could find a way to source nickel in both an environmentally sensitive and efficient way. Earlier this year, Tesla presented an investment proposal to the government of Indonesia. It’s safe to say it went well because the next day, the nation reported that new mining projects would not be allowed to discard waste into the ocean.
This move by Tesla demonstrates the power that companies have to demand only minerals that have been sourced responsibly to be used in their products. Companies must use this power to ensure that the road to a clean energy economy isn’t filled with human rights abuses and mine waste.
Any companies that have plans to make profit off of clean technology must therefore utilize their market power to ensure that the mined materials utilized in their products are responsibly sourced, whether it’s lithium from Argentina, cobalt from the Democratic Republic of Congo or nickel from Indonesia.
Doing this provides can provide companies with a marketing edge. And with pressure increasing from investors and consumers to make sure that mineral sourcing for low-carbon technologies and EV batteries, in particular, is as responsible as possible, other companies are bound to follow.
Meanwhile, many mining companies are well positioned for success in the years and decades to come. An example of one such company is Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), which is the holder of an enviable option to acquire the Silver City Project located in Germany. Historical records show that this location possesses enticing potential, with previous high-grade yields of 1kg. of silver for each ton of ore extracted.
NOTE TO INVESTORS: The latest news and updates relating to Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) are available in the company’s newsroom at https://ibn.fm/EXN
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics (“DTx”) market, today announced the company’s plans to participate in the upcoming Cowen 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021. According to the update, Dario’s CEO, Erez Raphael and Rick Anderson, president and general manager for North America, are scheduled to present in a virtual setting at 11:00 a.m. ET on Monday, March 1, 2021. Interested parties can access the live and archived webcast via the company’s website.
To view the full press release, visit: https://ibn.fm/nac7n
About DarioHealth Corp.
DarioHealth is a leading, global digital-therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital-therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
RIV Capital (formerly Canopy Rivers) (TSX: RIV) (OTC: CNPOF) has completed the previously announced plan of arrangement involving Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC). Under the arrangement, RIV Capital, through its wholly-owned subsidiary, RIV Capital Corporation (formerly Canopy Rivers Corporation), transferred its interests in TerrAscend Corp., TerrAscend Canada Inc., Les Serres Vert Cannabis Inc. (“Vert Mirabel”) (other than the shares transferred to Serres Bertrand), and The Tweed Tree Lot Inc. (collectively, the “transferred assets”) to Canopy Growth. The assets were transferred in exchange for approximately $115 million in cash, 3,647,902 common shares of Canopy Growth (having a value of approximately $170.3 million as at the close of trading on the Toronto Stock Exchange (the “TSX”) on Feb. 22, 2021), and the cancellation of all 36,468,318 multiple voting shares (“MVS”) and 15,223,938 subordinate voting shares (“SVS”) of RIV Capital held by Canopy Growth.
To view the full press release, visit: https://cnw.fm/AS4oH
About RIV Capital Inc.
RIV Capital is an investment and acquisition company specializing in cannabis with a portfolio of 14 companies across various segments of the cannabis value chain. The company believes that bringing together people, capital and ideas raises the potential of the entire cannabis industry. By leveraging its industry insights, in-house expertise, and thesis-driven approach to investing, RIV Capital aims to provide shareholders with exposure to specialized and disruptive cannabis companies.
NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://cnw.fm/CNPOF
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
In a groundbreaking study, two teams of researchers — one based at the University of South Australia in Adelaide and another in London — have shown that stroke recovery peaks at approximately two weeks after the stroke and then gradually diminishes with the passage of time.
The teams at Adelaide and London followed a total of 60 patients who had had a stroke. This follow-up lasted up to 12 months after the stroke.
Dr. Brenton Hordacre, based at the University of South Australia in Adelaide and also the lead author of the study, explained that this multisite study was intended to find out whether what was observed in animal studies could also be witnessed in human stroke survivors.
The team conducted scans on the brains of the victims using continuous transcranial brain stimulation (“cTBS”) to repeatedly activate different hemispheres of the victims’ motor cortex. The intention was to track brain plasticity in the victims. The laboratory in Adelaide focused on measuring plasticity within the damaged hemisphere of the motor cortex while the laboratory in London focused on the intact hemisphere of the motor cortex. This intact side is vital because it plays an important role in the recovery of the patient. Their assessments revealed that brain plasticity was at its highest 14 days post-stroke within the cortex that didn’t suffer any damage.
The lead author asserts that their findings confirm how important it is to initiate therapy immediately after someone has suffered a stroke.
The latest evidence shows that at the moment, a maximum of eight minutes is devoted each day to helping stroke victims recover function in their upper limbs in the first four weeks after a stroke. The research team believes that the treatment outcomes can be improved if more time is devoted to therapy within this window, as the chance of recovery decreases as time passes after the two-week mark.
Hordacre says more study and research needs to be done, despite the groundbreaking findings that they obtained in their study, which was published early this month. For example, he points out that attention needs to be directed towards identifying the specific therapy techniques that have the capacity to extend or even reopen the period when brain plasticity remains high after one has had a stroke. Such techniques have the potential to make full recovery a possibility, even in people who have suffered a severe stroke.
Many companies are currently investing significant resources in identifying conditions that affect the brain, such as Brain Scientific Inc. (OTCQB: BRSF). With a mission of modernizing brain diagnostics, Brain Scientific develops innovative and proprietary medical devices and software.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
In the 1950s, Oscar Janiger, a psychiatrist interested in LSD’s effect on creativity, dosed more than 950 individuals with the drug in his LA home. He carefully wrote down each individual’s experience and concluded at the end of his experiment that LSD could affect individuals who were already creative but could not make noncreative individuals more creative.
He recognized that while LSD couldn’t inspire an individual who wasn’t creative to suddenly begin writing poetry or painting, it did provide creative individuals insights into their craft’s nature.
Another researcher who was immensely interested in LSD, a chemist by the name of Albert Hoffman, spent years trying to learn more about this psychedelic substance. His discovery of LSD is what drove the entire neuroscience field to conduct numerous studies on the drug. The thousands of studies that were carried out in the ’50s and early ’60s drove science in a new direction.
Later, in 1973, American psychologist Timothy Leary forecasted that one day the world would be connected by a new electronic nervous system. He believed that psychedelics could help the advancement of technology. Cyberpunks later considered his prophetic message to be an internet-inspired vision.
This ushered in Silicon Valley, which was looking to build a future that was digitally connected. Steve Jobs, one of the founders of Apple, attributes LSD trips to being some of the most important things in his life. He admitted to having consumed sugar cubes that were laced with LSD a dozen or so times between 1972–1974. He later co-founded Apple with Steve Wozniak in 1976.
By now you may be asking yourself, “Did the computer revolution occur because of psychedelics?”
While many see Leary as the hippie-era cosmic clown, he did verify Janiger’s discovery that if individuals were critical thinkers, psychedelics could help them become more creative. The term “psychedelic,” which was coined in 1956 by psychiatrist Humphry Osmond, refers to “mind manifesting.” This would explain Leary’s knowledge on the human imagination having limitless potential for manifesting any idea, no matter how unconventional it was.
Various technological applications produced in Silicon Valley are a fruit of imagination, productivity-induced microdosing or both. One such application is Neuralink, a brain-machine interface that connects software with an individual’s thoughts. Even though it’s still in development, many are hopeful that this breakthrough invention could revolutionize various fields.
Another application has been developed through Cybin Inc. (NEO: CYBN) (OTC: CLXPF)’s partnership with Kernel, a firm of neuroscience tech makers. Their invention, an fMRI scanner, observes the activity of individuals’ brains when they are tripping. The partners hope that this consumer-grade device will become a household appliance by the 2030s.
There is still so much yet to be discovered with regard to psychedelics and how they influence technology. However, their promising potential indicates that great things lie ahead.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. The company’s pipeline includes Berubicin for the treatment of patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently focused on the development and clinical trials of Berubicin for GBM, as well as the potential of addressing other central nervous system malignancies. “The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase II trial in the U.S., and two trials planned by our sublicensee WPD in Poland,” CNS Pharmaceuticals CEO John Climaco said during a recent virtual presentation discussing the FDA IND approval and future company plans.
To view the full article, visit: https://ibn.fm/qhy8l
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Clean Power (CSE: MOVE) (OTC: MOTNF) (FWB: 2K6A) today provided additional information about how the onsite hydrogen production and dispensing technology being developed by PowerTap Hydrogen Fueling Corp., an investee company of Clean Power, will be used in other commercial markers. According to the update, PowerTap has commenced plans to commercialize its third generation units into new verticals such as commercial buses and trains, and has initiated partnership discussions with various cities and states/provinces. Subject to the progression of PowerTap’s plan to expand its product offering, its third generation onsite hydrogen production module will be made available to provide blue hydrogen for trains and buses, in addition to hydrogen fuel cell cars and trucks. A prime example of this growing market is the Coradia iLint, a hydrogen train built by Alstom in Salzgitter, Germany and currently being deployed in Europe*. The Corada iLint is the world’s first passenger train powered by on-board hydrogen fuel cells producing electrical power for traction. This relatively low-noise, zero-emission train only exhausts steam and condensed water as atmospheric outputs. “PowerTap continues to have discussions with various commercial opportunities in various verticals and will continue to update shareholders in the coming weeks and months,” said PowerTap CEO Raghu KIlambi.
To view the full press release, visit http://ibn.fm/gotUt
About Clean Power Capital Corp.
Clean Power specializes in investing into private and public companies opportunistically that may be engaged in a variety of industries, with a current focus in the health and renewable energy industries. In particular, the mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in the company’s investments. A copy of Clean Power’s amended and restated investment policy may be found under the company’s profile at www.SEDAR.com. For more information, visit the company’s website at www.CleanPower.capital.
*https://www.alstom.com/solutions/rolling-stock/coradia-ilint-worlds-1st-hydrogen-powered-train
NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at http://ibn.fm/MOTNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- PowerTap Hydrogen Fueling has signed a definitive agreement with the Andretti Group to create an optimized network by leveraging the latter’s operational expertise and global reach
- PowerTap plans to have 500 operational hydrogen filling stations deployed across the country by the end of 2025
- The existing business model’s deployment of hydrogen stations expedites rollout due to the existing fuel operations on each site
- The hydrogen fuel cell vehicle market worldwide was valued at $651.9 million in 2018 and is expected to grow to over $42 billion by 2026
Stemming from the announcement made by Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) on January 26, 2021, about the Definitive Agreement between investee PowerTap Hydrogen Fueling and the Andretti Group for the production and deployment of hydrogen fuel units across California, more details have been released regarding the agreed-on business model, as well as the agreement’s benefits for the parties involved (https://ibn.fm/WYoYt).
PowerTap is working to build and expand its hydrogen fueling station network, initially across North America, starting the second half of 2021. The platform is believed to be more cost-effective and expandable than other hydrogen filling station’s models. The significant advantage over these companies comes from PowerTap’s smaller physical footprint and capacity to produce hydrogen on-site. Other companies purchase hydrogen at high prices and store it.
To be eligible to host a hydrogen fueling station, a site needs to meet a series of requirements, including: to have an existing fuels retailer, a usable area of at least 1000 square feet, as well as access to utilities, including natural gas, electricity, and water.
The key points for the business model are:
- The retailer provides the land, with no leasing expenses required of PowerTap
- PowerTap, at their own expense, will install and maintain the modular hydrogen production and dispensing unit. These expenses also include branding costs and utilities.
- The retailer will market hydrogen fuel and generate profit the same way traditional fuel sales are conducted.
Under the agreement, participating retails have a number of advantages, including:
- A high-yield opportunity to create revenue out of the land that is not being used to full potential
- Retailers are eligible to receive a portion of the carbon credit revenue
- Minimal operating costs and high earnings as an additional means of profit
- New clientele group, generating additional purchases of other products or services
- The on-site production allows a competitive price (go-to-market) versus the delivered supply price
The advantages for PowerTap include:
- No land purchase or leasing expenses
- Co-development that provides access to prime and higher trafficked real estate
- A faster entitlement process due to the existing fuel operation
- Ability to leverage the Andretti Group’s established operations expertise and geographical reach for a more optimized network
- Ability to expedite rollout, with the deployment of over 500 PowerTap modular hydrogen production and dispensing units by the end of 2025
The PowerTap technology has already been deployed across multiple hydrogen fueling stations in both public and private enterprises. These can be found in California, Maryland, Massachusetts, and Texas. By the end of 2025, PowerTap plans to deploy over 500 stations at existing truck stops and gas stations across the country. At present, there are under 100 active hydrogen fueling stations operational and available to consumers.
The hydrogen fueling network plan enables PowerTap and by extension Clean Power Capital to access a fast-growing market rife with expansion opportunities. According to Allied Market Research, the global hydrogen fuel cell vehicle market, valued at $651.9 million in 2018, is expected to grow at a CAGR of 66.9% to 2026, reaching an estimated value of $42,038.9 million (https://ibn.fm/Rg9Te). The key factor influencing the push for hydrogen fuel vehicles is the surge in environmental concerns over traditional fossil fuels. Hydrogen fuel does not generate greenhouse gas (“GHG”) emissions during operation like diesel and gasoline-powered vehicles.
The United States is already engaging in the hydrogen economy and currently leads in the number of hydrogen cell vehicles globally. The government is investing hundreds of millions of dollars per year in the hydrogen fuel industry, helping potentially create approximately 3.4 million jobs within the next three decades (https://ibn.fm/qF0M4).
For more information, visit the company’s website at www.CleanPower.Capital.
NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. As scientists work to understand what causes Parkinson’s, Alzheimer’s, dementia and other neurological issues, BRSF is making inroads in helping identify root neurological problems. The company has unveiled a new initiative to develop an innovative e-tattoo device for the brain diagnostics market. The Brain E-Tattoo’s graphene-based electrodes are designed for connection to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. The solution enables each patient’s data to be secured in the cloud where Brain Scientific’s artificial intelligence performs continuous analysis, providing 24/7 uninterrupted seizure monitoring. Dating back to 1929, drastic advances to the EEG have only been seen in the last few decades. “COVID-19 put a spotlight on the outdated and inefficient EEG testing protocols,” said Boris Goldstein, BRSF co-founder and executive. “Disposable technology made a significant impact to ensure brain scans could occur safely during the pandemic. Now, brain e-tattoos implanted in the forehead will be the next wave of innovation for neurology. The advancement will allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions. Clinicians will be able to identify brain wave activity beyond the clinical setting with no impact to the patient’s daily life. While we aren’t yet ready as a society to cyborg our way past neurological issues, we are on the cusp of better understanding and diagnosing them. Thanks to cutting-edge technology like BRSF’s E-Tattoo, answers are right around the corner.”
To view the full article, visit: https://ibn.fm/O1DOu
About Brain Scientific Inc.
Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The coronavirus pandemic has impacted various sectors, including the environment, economic, social and health industries. While the vaccine has given people hope, the absence of a strategy that will be used to dispose of any coronavirus-related biomedical waste remains a threat.
The Central Pollution Control Board in India recently released data showing that between June and December 20202, the coronavirus-related biomedical waste that was generated measured an estimated 33,000 tons. Earlier in July, the board presented a report to the National Green Tribunal indicating that India generated 101 MT of coronavirus-related biomedical waste daily and an additional 609 metric tons through other means.
In the country, cities that had experienced high numbers of coronavirus cases are now dealing with the problem of contaminated/used PPEs, including shoe covers, gloves and masks being dumped out in the open or with household waste. This is despite the fact that PPE kits had been restricted for use by medical personnel only. By disposing personal protective equipment kits with regular garbage, the persons living in those areas have posed a great risk to the ecosystem.
While coronavirus care centers and hospitals have put in place measures for the sorting of waste, the unscientific disposal of coronavirus biomedical waste by private contractors and corporations is alarming. There is no method to check whether waste has been stored properly before it is incinerated, and neither is there a way to track trucks that carry biomedical waste.
The government of India and the World Health Organization (“WHO”) offered guidelines on how to discard coronavirus-related biomedical waste, which include protection for sanitation workers and proper separation of waste. However, the pandemic has affected the garbage disposal chain, which has disrupted temporary storage, transport, sorting and waste management of biomedical waste. Additionally, proper sorting of wet and dry waste is still not adhered to, which is also affecting the disposal chain.
Furthermore, sanitation workers are rarely provided with adequate PPE kits, water and soap, which are basic necessities during this pandemic. It doesn’t help that these workers are usually underpaid by municipal corporations with safety guidelines often not enforced. This means that proper balances and checks are rarely conducted to ensure the workers’ safety.
In addition to this, biomedical waste has also impacted the animals, soil, water and air. As India doesn’t have proper water treatment plants for sewage, most sewage water, which contains feces and fluids of coronavirus patients, flows into bodies of water bodies such as the sea and rivers. This will contaminate the water bodies and, with researchers still unsure of the long- and short-term effects of this pollution, many remain concerned.
To what extent is this biomedical waste disposal problem playing out in different countries around the globe?
Away from the issues of biomedical waste disposal, lots of companies are doing a lot to find treatments for some of the most challenging conditions. An example is AzurRx BioPharma Inc. (NASDAQ: AZRX), which has completed two Phase 2 clinical trials on a drug candidate intended to treat EPI (exocrine pancreatic insufficiency) among chronic pancreatitis sufferers and those with cystic fibrosis.
NOTE TO INVESTORS: The latest news and updates relating to AzurRx BioPharma Inc. (NASDAQ: AZRX) are available in the company’s newsroom at https://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Amesite(NASDAQ: AMST) founder and CEO Dr. Ann Marie Sastry is scheduled to present at the Diamond Equity Research Emerging Growth Invitational. The one-day premier event will be held on Wednesday, Feb. 24, with Sastry’s presentation scheduled for 12:20 p.m. ET. During her presentation, Sastry will provide an overview of the Amesite story and discuss how the company’s award-winning, highly scalable artificial intelligence (“AI”) driven platform is impacting the way the world learns. A live audio webcast and archive of the conference presentation will be available using the registration link. AMST operates in a U.S. online learning market of $350 billion and is becoming recognized for its cloud-based online learning platform that is considered the most advanced in the industry. Amesite is a high-tech artificial intelligence software company offering a cloud-based platform and content creation services for business, university and K-12 learning and upskilling. “I look forward to sharing our story with the investment community,” said Amesite founder and CEO Ann Marie Sastry in the press release. “Online learning is the future of professional and student education and we are well-positioned to serve this large and growing global multi-trillion-dollar market, and deliver more engaging, effective and accessible learning experiences for all.”
To register for the conference, visit http://ibn.fm/70s3k
To view the full press release, visit http://ibn.fm/kAFsi
About Amesite Inc.
Amesite is a high-tech, artificial intelligence software company offering a cloud-based platform and content creation services for business, university and K-12 learning and upskilling. Amesite-offered courses and programs are branded to its customers. For more information about the company, please visit www.Amesite.com.
NOTE TO INVESTORS: The latest news and updates relating to AMST are available in the company’s newsroom at http://ibn.fm/AMST
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Hollywall Entertainment (OTC: HWAL), an innovative telecommunication and broadcasting company, has begun the rollout of its new wholly owned subsidiary HW Vision. According to a recent update, the subsidiary will provide branded cellular equipment and services, streaming media content, live television and on-demand programming as part of Hollywall’s drive to become a major media and entertainment conglomerate. An article discussing this reads, “HWAL’s subsidiary HW Vision will be advancing its technological footprint via its entry into an agreement to acquire top United States telecommunications firm Omnipoint Technology Inc., a Massachusetts-based telecommunications company, to deliver the services — including content from Hollywall’s large entertainment library and educational programming catalogue — to residential homes and commercial businesses through its network across the Eastern and Southern United States.”
To view the full article, visit https://ibn.fm/nr5GV
About Hollywall Entertainment Inc.
Hollywall Entertainment is a telecommunications, technology, media, entertainment and broadcasting company that operates through its various subsidiaries including: Hollywall Development Company (“HWDC”), HW Vision and HW Latlong, and multiple divisions to include HW School of Communications, Hollywall Music, Hollywall TV, HW Productions, HW Networks, HWRadio, HWGOV and The Hollywall Foundation. HWAL continues to maximize rights to its music, film, television, home videos and software game libraries. Hollywall owns exclusive and nonexclusive rights to market, manufacture and distribute music master recordings performed by legends such as Ray Charles, Ella Fitzgerald, The Jackson 5, Frank Sinatra, Dolly Parton, Elvis Presley, Tony Bennett, The Bee Gees, Chicago, The Platters, George Gershwin, Marvin Gaye, James Brown, The Who, Janis Joplin, Rolling Stones, Nat King Cole, John Lee Hooker, Willie Nelson, Rod Stewart, Hall and Oates, James Taylor, Etta James, Aretha Franklin, and other multiple-platinum-selling acts. Learn more at www.Hollywall.com.
NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at http://ibn.fm/HWAL
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) announced that it has accelerated the creation of a commercial team formed to launch its point-of-care COVID-19 RT-PCR (“RT-PCR”) test system, called the COVID ID Lab. The lab was developed by XPhyto’s exclusive German diagnostics development partner, 3a-diagnostics GmbH (“3a”). It is anticipated that 3a will receive ISO 13485 medical device manufacturer approval by the end of February; European regulatory approval should be received by early March. The announcement noted that the market launch team consists of highly skilled clinical and pharmaceutical executives and service providers with the expertise and background to rapidly drive the commercialization of Covid-ID Lab. “We are extremely fortunate to now have a team with deep expertise in medical diagnostic product commercialization,” said XPhyto CEO and director Hugh Rogers in the press release. “The team has extensive experience from regulatory approval to international production and sales. As we near expected regulatory approval, XPhyto’s business is rapidly evolving from innovation to impact. We are working hard to put the Company in the best possible position to execute on our business strategy.” XPhyto also released a statement regarding a claim made against Vektor Pharma TF GMBH (“Vektor”), one of its German subsidiaries. The claim notes that “Vektor is subject to a declaratory action made by a former client and current competitor in relation to alleged breach of the terms of a development agreement between Vektor and the claimant. The claimant has estimated its alleged damages at 1 million Euros. Vektor and management of the corporation believe the claim is substantially without merit and intend to defend the claim vigorously. Vektor has filed a notice of defense in the respective German court. In the event that a court finds Vektor to be liable for damages, even in the amount estimated by the Claimant, such judgment is not expected to have a material adverse effect on the business or affairs of Vektor or the corporation. The corporation will provide further updates as the action progresses.”
For more information, visit https://ibn.fm/UV279 and https://ibn.fm/qjVMJ
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at http://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Life sciences industry accelerator XPhyto Therapeutics Corp. has developed a timeline for the approval and rollout of a rapid, portable COVID-19 test it expects to become available by April in Europe
- XPhyto’s Covid-ID Lab system is designed to help industries economically devastated by the pandemic to form strategies based on quick and accurate testing, particularly the travel industry
- The company intends to use its test tech partnership with Germany’s 3a-diagnostics GmbH to build additional bacteriological and viral testing products
- A separate subsidiary based in Alberta is developing psychedelic medicine programs
- The subsidiary recently announced it has added mescaline production to the program for potential use in treating addiction and depression
Canada-based bioscience accelerator XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has completed all the preparatory actions necessary for it to apply for approval of its COVID-19 rapid and portable test system under European regulatory authorities, the company announced Feb. 16.
The quick-response point-of-care SARS-CoV-2 RT-PCR Test System known as “Covid-ID Lab” developed in partnership with Germany’s 3a-diagnostics GmbH is designed to provide robust and accurate COVID-19 testing for economically devastated market sectors, with particular emphasis on travel industries. The announcement is one of a pair of company developments to emerge this month, including the expansion of the holding company’s psychedelic medicine programs.
In regard to the COVID test, 3a expects to obtain approval as a medical device manufacturer under internationally agreed-on ISO 13485 quality standards by late February, followed by European regulatory approval of Covid-ID Lab as a commercial in vitro diagnostic device (CE-IVD) by early March, according to the company’s announcement (https://ibn.fm/89jKh).
The companies then plan for manufacturing to begin in Germany with an April target for Covid-ID Lab’s sales launch in Europe. XPhyto is building relationships with partners in other countries to further advance the system’s sales and distribution.
“Our goal was to create the fastest and most portable COVID-19 PCR test on the market,” XPhyto CEO and Director Hugh Rogers stated. “We are very pleased with the team’s swift development progress.”
The pandemic has had a calamitous effect on the tourism industry during the past year, especially for popular island destinations ranging from Hawaii to Australia and New Zealand. Domestically, Hawaii has experimented with resort “bubbles” and recently announced a test-dependent Health Pass agreement that will help travelers avoid a mandatory 10-day quarantine once they arrive on the islands (https://ibn.fm/yuQQd), while United Airlines became the first U.S. carrier to establish an in-airport testing partner and information service, according to a CBS News report (https://ibn.fm/Af5A6).
But the growing spread of COVID virus variants from the United Kingdom, South Africa and Brazil is creating new urgency about safeguarding international travel. India’s new air travel guidelines issued Feb. 18 are just the latest efforts to limit transmission of the worldwide health crisis, and experts believe varied restrictions will remain in place for a long time to come.
“Like 9/11 changed air security forever, we’re still taking our shoes off,” XpresCheck CEO Doug Satzman stated in the CBS News report. “COVID is going to change safety protocol in airports for a long time as well.”
The U.S. Centers for Disease Control and Prevention (“CDC”) has advised against such travel entirely, but has added testing recommendations for people who ignore its advice. In late January, the agency broadened international travel requirements, making negative COVID tests mandatory for passengers coming from any international location to the United States despite airline industry resistance (https://ibn.fm/rnoG3).
XPhyto’s rapid-response test system aims to give businesses and government authorities a powerful tool in their arsenals, and the COVID response is only the beginning. The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, and is focusing on other potential pandemic biosensor tech efforts to combat the spread of the H1N1 (swine flu) and H5N1 (avian flu) viruses.
The company states it is planning to launch its first biosensor product commercially during the latter half of 2021.
Elsewhere, one of XPhyto’s holdings in Canada, XPhyto Laboratories Inc., has added mescaline production to its psychedelic medicine programs, according to a Feb. 3 announcement (https://ibn.fm/zyiEL).
Mescaline is listed as a Schedule I drug in the United States without legally recognized medicinal benefits and with a high risk of abuse, but the psychedelic substance occurs naturally in some types of cactus and has limited legal use in certain religious ceremonies registered by the Native American Church and in certain research efforts. However, its use is expanding internationally as a supplement to various types of meditation and psychedelic therapies, according to the company.
“Mescaline has been anecdotally recognized as a relatively safe psychedelic drug and has shown particular promise for the treatment of addiction and depression,” XPhyto’s news release states.
For more information, visit the company’s website at www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
TEMPE, Ariz., Feb. 22, 2021 — Wrap Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRAP ), an innovator of modern policing solutions, reported the successful deployment of the BolaWrap by the Buffalo Police Department while responding to a mental health call of a woman in crisis on Friday.
In September of 2020, Buffalo Mayor Byron Brown and the Buffalo Police Department held a press conference to discuss and demonstrate BolaWrap for the public.
In October of 2020, Mayor Brown and Common Council President Darius Pridgen announced the launch of a BolaWrap pilot program as part of an innovative public safety initiative.
In January of 2021, CBS-affiliate WIVB reported that the pandemic had pushed back training sessions for the equipment, but that police officials had announced training for the BolaWrap would start in the next couple of weeks.
On Friday, less than one month after BolaWrap training began, Buffalo Police Department successfully deployed the BolaWrap on a women in mental crisis, enabling them to take her into custody and transport to a mental health facility without injury, as reported by WIVB and NBC-affiliate WGRZ .
According to WGRZ,
‘At around 2 p.m. Friday near Kenfield-Langfield, police received a call with concern about a woman who may have the potential to cause harm to herself or others and was underdressed in the snow. Police were concerned about hypothermia exposure for the woman.
Police say they spoke with the woman for an extended period of time, asking her to get in a police car and receive medical evaluation. The woman refused, which police say prompted them to deploy the Bolawrap.
The device allowed police to transport her to Erie County Medical Center for evaluation without anyone getting hurt, according to police.’
“Public safety includes solutions that can de-escalate encounters, and that’s exactly what the BolaWrap does,” said Tom Smith, President of WRAP. “BolaWrap doesn’t rely on pain compliance and is designed to de-escalate situations and provide needed support for persons in crisis. We are pleased to continue seeing successful field deployments of the BolaWrap, especially by the police department of New York’s second-largest city.”
In October of 2020, Smith participated in City & State’s 2020 Protecting New York Summit alongside NYC Public Advocate Jumaane Williams, NYC Councilmember Donovan Richard, and industry executives for a solutions-oriented discussion on reimagining public safety in New York. WRAP sees the Buffalo pilot program as an important element of public safety in New York.
About WRAP
WRAP Technologies, Inc. is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in a number of cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge. For information on the Company, please visit www.wrap.com.
Follow WRAP here:
WRAP on Facebook: https://www.facebook.com/wraptechnologies/
WRAP on Twitter: https://twitter.com/wraptechinc
WRAP on LinkedIn: https://www.linkedin.com/company/wraptechnologies/
Trademark Information
BolaWrap and Wrap are trademarks of WRAP Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.
Cautionary Note on Forward-Looking Statements – Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to: statements regarding the Company’s overall business; total addressable market; and, expectations regarding future sales and expenses. Words such as “expect”, “anticipate”, “should”, “believe”, “target”, “project”, “goals”, “estimate”, “potential”, “predict”, “may”, “will”, “could”, “intend”, and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Moreover, forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors mentioned in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
WRAP Contact:
Paul M. Manley
VP – Investor Relations
(612) 834-1804
pmanley@wrap.com
- American Psychiatric Association poll reveals 62% of respondents have anxiety about COVID-19
- Recent FDA Drug Safety Communication requires updated Boxed Warning for benzodiazepines commonly used to treat anxiety disorders
- VTGN is committed to developing and commercializing PH94B, a first-in-class pherine nasal spray with potential to go beyond the current standard of care for acute treatment of social anxiety disorder and other anxiety-related disorders
Anxiety induced by the COVID-19 pandemic during the last year has been linked with surging use of benzodiazepines or “benzos,” a drug class commonly prescribed to treat anxiety and other disorders – a trend with potential to create a new wave of misuse, overuse and addiction among users while leaving physicians concerned about long-term detrimental side effects (https://ibn.fm/FFhjW). As a proactive response to what many critics are calling a “benzo epidemic” (https://ibn.fm/777mk), VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company headquartered in South San Francisco, is currently committed to developing a new generation of medicines that go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders. VistaGen’s CNS pipeline includes multiple innovative drug candidates for treatment of anxiety and depression disorders, each of which has demonstrated favorable safety results in all clinical studies to date and significant commercialization potential in multiple neuropsychiatric markets.
Anxiety is on the rise, according to a recent poll by the American Psychiatric Association, revealing that up to 62% of respondents have serious concerns about the effects of COVID-19 on themselves or loved ones. Additionally, prescriptions for benzodiazepines spiked 34% during the early stages of the pandemic according to a study of over three million people, suggesting a link between the rise of anxiety and increased coverage of the COVID-19 issue in the media.
The use of benzodiazepines to treat anxiety has grown steadily since their discovery in the 1950s. Commonly classified as “minor tranquilizers,” benzodiazepines are prescribed to treat anxiety, panic disorders and seizures by calming nerve impulses and creating a sense of relaxation and well-being. Unfortunately, however fast-acting and highly effective they may be, benzodiazepines are also extremely addictive, earning them a Schedule IV controlled substance classification by the Drug Enforcement Agency (“DEA”) due to their potential for abuse. In September 2020, the FDA’s Drug Safety Communication (“DSC”) noted that there were 92 million prescriptions of benzodiazepines in 2019 and also detailed safety concerns regarding the serious risks of abuse, addiction, physical dependence, and withdrawal reactions linked to long-term use of benzodiazepines. As a result, in the DSC, the FDA announced that it is requiring an updated Boxed Warning, the FDA’s most prominent type of safety warning, for all benzodiazepine medications (https://ibn.fm/08UKT).
According to many medical practitioners, benzodiazepines have serious long-term consequences. Use of the drug has been associated with the development of an increased tolerance that requires higher amounts to achieve the same effect. Additional long-term consequences include addiction, future cognitive problems and incapacitating withdrawal symptoms.
VistaGen is committed to developing therapies that go beyond the limits of the current standard of care. To advance on that goal, VistaGen is currently preparing to launch Phase 3 clinical development of its PH94B for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”), the third most common mental illness among Americans. PH94B is a first in class pherine nasal spray designed with potential to deliver the rapid-onset anti-anxiety effects of benzodiazepines, but without the side effects and safety concerns associated with their use. VistaGen currently anticipates launching its U.S. Phase 3 development program for acute treatment of SAD during the second quarter of this year. The Company is also planning to launch exploratory Phase 2 studies in 2021 focused on several additional anxiety-related disorders, including adjustment disorder, postpartum anxiety, and pre-procedural (pre-MRI) anxiety (https://ibn.fm/bVbBy).
For more information, visit the company’s website at www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Shares of Uranium Energy Corp. (NYSE American:UEC) traded at a new 52-week high today of $2.56. This new high was reached on below average trading volume as 2.5 million shares traded hands, while the average 30-day volume is approximately 5.1 million shares.
Uranium Energy Corp. (NYSE American:UEC) is currently priced 14.3% above its average consensus analyst price target of $2.16.
Uranium Energy Corp is engaged in the uranium mining and related activities, including exploration, pre-extraction, extraction and processing, on uranium projects located in the United States and Paraguay. In South Texas, the company’s hub-and-spoke operations are anchored by the fully licensed Hobson processing facility which is central to the Palangana, Burke Hollow and Goliad ISR projects. In Wyoming, it controls the Reno Creek project, which is the largest permitted, pre-construction ISR uranium project in the U.S. Additionally, the company controls a pipeline of uranium projects in Arizona, New Mexico and Paraguay, a uranium/vanadium project in Colorado and the highest-grade and largest undeveloped Ferro-Titanium deposits in the world, located in Paraguay.
In the past 52 weeks, shares of Uranium Energy Corp. have traded between a low of $0.35 and a high of $2.56 and is now at $2.52, which is 620% above that low price.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
TAAT(TM) Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2), a life sciences company dedicated to giving legal-aged smokers the choice to keep the smoking experience that they enjoy with no nicotine and no tobacco, reported more than C$50,000 sales from its online site in the first two days of being live; that number had grown to more than C$100,000 by the end of the weekend. Orders placed through the site, which was launched on Wednesday, Feb. 17, at 9 a.m. ET, were shipped to more than 20 different U.S. states. The site offers cartons of TAAT(TM) Original, Smooth and Menthol for purchase as well as a Taste Explorer Bundle consisting of one 20-stick pack of each of the three TAAT varieties. The announcement noted that TAAT has also added new retail points of sale throughout the state of Ohio, where the company launched retail sales of its product in December 2020. “To sell more than C$100,000 worth of a relatively new product in such a short period is absolutely exceptional,” said TAAT CEO Setti Coscarella in the press release. “Countless smokers aged 21+ in the United States have been eagerly awaiting the launch of our online store on Wednesday, which I believe has contributed significantly to our product sales this past week. Our iterative rollout of TAAT in the United States has been very strategically planned to test the initial reactions of smokers aged 21+ when introduced to the concept of a nicotine-free and tobacco-free smoking experience, while also gauging reception of the product after it is sampled for the first time. Over the past two months, we have had the opportunity to gather quite a bit of feedback about TAAT from smokers aged 21+ as well as retailers and wholesalers of tobacco. I believe those insights have proven useful, as they played a role in creating our strategies for launching the TAAT online store on Wednesday, which has been a remarkable success so far.”
To view the full press releases, visit http://ibn.fm/IuAji and http://ibn.fm/ajFYu
About TAAT Lifestyle & Wellness Ltd.
TAAT Lifestyle and Wellness has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.
NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://ibn.fm/NqQs7. The report reads, “Processa’s pipeline is constructed of development-stage assets that have substantial legacy human data, where the company believes a new approach (dosing, indication, trial design, etc.) can unlock latent value. Processa’s management (David Young, Questcor) and board (Khalid Islam, Gentium and Fennec) have a history of successful drug reclamation projects. The company’s lead asset, eniluracil or PCS6422, was a GSK drug that has been studied in over 1,500 cancer patients, where Processa believes slight changes to the dosing regimen and study design can address previous shortcomings. The other pipeline product of note, PCS499, comes from Concert Pharmaceuticals, where it was studied in Ph2 for diabetic nephropathy, but Processa believes it is better suited for a rare dermatology indication, Necrobiosis Lipoidica (‘NL’). We are enthusiastic about both assets, in particular PCS6422, and feel if there is latent value in either or both, this is the team that can unearth it.”
To view the full press release, visit: https://ibn.fm/xBlGX
About Processa Pharmaceuticals Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at http://ibn.fm/PCSA
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
TEMPE, Ariz., Feb. 18, 2021 — Wrap Technologies, Inc. (the “Company” or “WRAP”) (Nasdaq: WRAP ), an innovator of modern policing solutions, will hold a Zoom video webcast on Thursday, March 4, 2021 at 4:30 p.m. Eastern time to discuss its financial and operational results for the fourth quarter and full year ended December 31, 2020. Financial and operational results will be issued in a press release prior to the webcast.
WRAP management will host the presentation, followed by a question and answer period. To RSVP for the event in advance, please click here .
Date: Thursday, March 4, 2021
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
RSVP: Webcast Registration Link
Please join the webinar 5-10 minutes prior to the start time. An archived replay will be available after the presentation ends via the investor relations section of the company’s website .
About WRAP
WRAP Technologies, Inc. is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in a number of cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge. For information on the Company, please visit www.wrap.com.
Follow WRAP here:
WRAP on Facebook: https://www.facebook.com/wraptechnologies/
WRAP on Twitter: https://twitter.com/wraptechinc
WRAP on LinkedIn: https://www.linkedin.com/company/wraptechnologies/
Trademark Information
BolaWrap and Wrap are trademarks of WRAP Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.
WRAP Contact:
Paul M. Manley
VP – Investor Relations
(612) 834-1804
pmanley@wrap.com
- Mental health experts note growing concern over impact of COVID-19 on nation’s mental health
- Compounding stress could have serious health, social consequences
- VTGN offers new hope to those dealing with depression disorders
A new survey from the American Psychological Association (“APA”) shines a spotlight on the growing concern about the impact of the global pandemic on the nation’s mental health (https://ibn.fm/ukaIx). These rising numbers, as well as the treatment for mental health illness and disorders, is of great concern to VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medications that goes beyond the standard of care for anxiety and depression.
Nearly eight in ten adults (78%) report that the coronavirus pandemic is a significant source of stress in their lives, while three in five (60%) say the number of issues America faces is overwhelming to them, according to the “Stress in America(TM) 2020: A National Mental Health Crisis” survey conducted by the Harris Poll on behalf of APA. The survey goes on to note this sobering statistic: Nearly one in five adults (19%) say their mental health is worse than it was at this time last year.
APA CEO Arthur C. Evans Jr. noted that “this survey confirms what many mental health experts have been saying since the start of the pandemic: Our mental health is suffering from the compounding stressors in our lives. This compounding stress will have serious health and social consequences if we don’t act now to reduce it. We’re already seeing this with some of the youngest members of our nation, who just seven months into this crisis are beginning to show signs of serious mental health issues, such as depression and anxiety.”
Depression and anxiety are at the forefront of concern for VistaGen, a company working to develop innovative product candidates to address these substantial issues (https://ibn.fm/vLnl9). For example, FDA-approved oral antidepressants are slow to act and are associated with significant potential side effects such as anxiety, nausea and vomiting, somnolence and sexual dysfunction. VistaGen’s PH10 is an innovative pherine nasal spray designed to have rapid-onset therapeutic potential in several neuropsychiatric indications involving depression. Following completion of successful exploratory Phase 2A clinical development, the Company is preparing to launch a planned Phase 2B clinical study of PH10 in major depressive disorder in early 2022. With its rapid-onset pharmacology, potential lack of systemic exposure and favorable safety results observed in all clinical studies to date, PH10 has potential to go beyond the current standard of care for depression as a novel stand-alone treatment for multiple depression disorders.
For more information, visit the company’s website at www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- SRAX’s Sequire has announced that 3 million retail investors are now using its investor intelligence platform
- Sequire’s growth had been predicated on its broad product offering, provision of digital investor–relations tools
- Sequire recently purchased LD Micro, a small and micro-cap company focused platform, to further bolster corporate presence
SRAX (NASDAQ:SRAX), a digital marketing pioneer focused on providing consumer data management services, recently revealed that Sequire, its investor intelligence SaaS platform, had grown to having over 3 million retail investors on its platform (https://ibn.fm/AzKzM). Launched as a stand-alone platform in early 2020, Sequire has seen its growth accelerate at an astounding rate – with the mix of investors and traders currently using its platform rising from 1 million to 3 million in a matter of mere months. The company has also attracted over 91 publicly-listed companies as subscribers on its platform (https://ibn.fm/5ZKtk) – an explosion of growth largely driven by Sequire’s extensive range of services.
Sequire’s popularity has largely predicated on the breadth of its platform and the unique suite of products available to the company’s corporate subscribers. With companies increasingly looking to adopt digital technology and the data generated from such mediums as a way of improving their engagement with investors and stakeholders alike, Sequire has sought to bridge the gap between publicly-listed corporations and…
Read more »
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into securities purchase agreements with certain institutional and accredited investors to raise approximately $17.6 million through the issuance of an aggregate of 9,043,766 shares of its common stock and warrants to purchase up to an aggregate of 4,521,883 shares of common stock, at a purchase price of $1.95 per share of common stock and associated warrant. The private placement is priced at-the-market under Nasdaq rules. Subject to the satisfaction of customary conditions, the closing of the private placement is expected to occur on or about Feb. 22, 2021. H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering. Predictive Oncology intends to use up to approximately $5.88 million of the net proceeds to repay certain indebtedness and the remaining net proceeds for general corporate purposes.
To view the full press release, visit: https://ibn.fm/9Rw9l
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Results from various studies conducted by leading research institutions in the Unites States have found that wearables such as smartwatches, which measure an individual’s heart rate, also possess the ability to identify whether a person is coronavirus positive — even before symptoms start showing or the virus is detected using a test.
These results, which were announced from institutions including Stanford University, California and New York’s Mount Sinai Health System, demonstrate that these devices detect the virus’s presence by measuring the pulse of a person’s heartbeat and their skin temperature as well as other biometric and physiological features.
Some of the devices mentioned in the report include Fitbit and Garmin watches and the Apple Watch. Experts state that the technology these devices use may be useful in the future to help decrease the spread of both the pandemic as well as other transmissible diseases.
A few members of the research team stated that their objective was to utilize the technology available to discover how fast the coronavirus or any other infection could be identified even before laboratory tests were conducted or symptoms begun showing.
Icahn School of Medicine assistant professor Rob Hirten explained that the goal of the study was to detect infections before individuals discovered they were sick or even identify the time an individual became infected. He further explains that the researchers were aware of the inflammatory effect the coronavirus had on the human body, adding that the variability markers of an individual’s heart rate changed as inflammation advanced in the body. This knowledge, he said, could help researchers predict when individuals were infected with a disease.
The researchers stated that to conduct the study, they observed 300 health-care personnel from Mount Sinai who wore Apple Watches over a five-month period, between April 29 and September 29, 2020.
The researchers also quoted a report conducted by the Centers for Disease Control in the U.S., which explained that a considerable amount of transmission takes place by carriers who were asymptomatic. They then noted that their findings would be useful in effectively containing the spread of the coronavirus.
The researchers’ interview, which was conducted by CBS, also highlighted a separate study that demonstrated the difference in the rates of heartbeats of some COVID-19 patients before the disease’s symptoms began showing. Additionally, alarm systems were developed for the wearable devices, which would notify a wearer about their heartbeat rates while also ensuring they kept a distance from individuals who had shown any signs of infection.
In most cases, the body may have a fighting chance against different diseases if matters of nutrition are accorded the attention they deserve. Nutrition and nutrients are a top priority for MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), a company that focuses on developing natural crop protection remedies that can reduce or eliminate the use of synthetic chemicals during cultivation.
NOTE TO INVESTORS: The latest news and updates relating to MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) are available in the company’s newsroom at https://ibn.fm/MGROF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Massachusetts General Hospital is partnering with Atai Life Sciences to study the effects of psychedelics on the human brain.
Atai Life Sciences is a biotech firm focused on developing medications to manage schizophrenia while also working on creating alternative treatments for various mental health conditions such as anxiety and depression.
The two organizations decided to work together after the hospital set up a program, named the Center for Neuroscience of Psychedelics, to study psychedelic therapy. A psychiatric at the hospital, Jerrold Rosenbaum is the head of the program and has specialized in the treatment of psychiatric disorders. Rosenbaum stated that there was a need to better comprehend the effects that psychedelics had on the human brain.
Rosenbaum revealed that he became interested in the psychedelic therapy field after a friend began studying the subject, which prompted Rosenbaum to reevaluate his perceptions on psychedelic substances. His friend is now serving as the director of the Center for Neuroscience of Psychedelics advisory council.
Rosenbaum explained that in the beginning he perceived hallucinogens as recreational drugs that had been banned from being studied for many years. However, as he begun to learn more about the substances, he realized that psychedelics presented an opportunity that had yet to be developed.
The Center for Neuroscience of Psychedelics is currently focused on neuroplasticity, which refers to the ability of the cells in the brain to alter themselves. Recent research has demonstrated that psychedelics enhance this activity in the brain, which may change how depression influences the brain.
Atai’s chief scientific officer Srinivas Rao explained that psychedelic therapy would help boost the effects of psychedelic substances by making use of the neuroplastic state. Atai and Massachusetts General are not revealing the particular substances that will be tested in the lab or on animals; neither are they disclosing the financial terms of their partnerships. However, Stephen Haggarty, who is the hospital’s researcher co-leading the collaboration, stated that it would involve psychedelics that were not similar to psilocybin, describing them as the next generation of psychedelics. Additionally, Haggarty stated that the molecule showed a lot of potential based on reports of the molecule in human beings.
Earlier in November, Atai Life Sciences had announced that it had raised more than $125 million in financing, which would be used to support the testing and development of psychiatric treatments. This brought the company’s total funding to roughly $250 million.
Atai Life Sciences was established in 2018 by Compass Pathways as a way for the organization to raise funds.
Atai isn’t the only company looking to develop psychedelic medicines. Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is also intent on developing psychedelic medicines, especially given the encouraging preliminary research results showing the potential of these substances in treating mental illnesses.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (8SV1.F) (“WPD”), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wroc¿aw, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Multiforme (“GBM”) under the WPD-201 Clinical Trial Protocol. CNS Pharmaceuticals has received study level approval from the Central IRB for the CNS-201 Clinical Trial Protocol. Berubicin is the company’s novel anthracycline candidate for the treatment of a number of serious oncology indications, currently in development for the treatment of GBM. CNS entered into a sublicense agreement with WPD in November 2019, which provided WPD the commercial rights to Berubicin in select territories in Europe and Asia. “We are pleased for WPD to achieve this key milestone and are encouraged by their continued execution in furthering the development of Berubicin,” said John Climaco, CEO of CNS Pharmaceuticals. “Importantly, we believe WPD’s Ethics Committee approval of the WPD-201 Clinical Trial Protocol coupled with our recent IND approval and Central IRB Study Level approval, position us one step closer to collaboratively initiating three clinical trials for Berubicin during 2021. We look forward to continuing our trial preparations, as well as WPD’s planned submissions to the Polish Competent Authority.”
To view the full press release, visit: https://ibn.fm/qNRoS
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of the first quarter of 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
